Early clinical trials showed promising results with durable anti-tumor immune responses [25], which led to the approval of multiple PD-1- and PD-L1-targeting monoclonal antibodies for therapeutic use in various cancer types (Table 1). This evidence concerns the gene CD274 and neoplasm.